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biomarkers into localized prostate cancer
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Marco Moschini1, Martin Spahn2, Agostino Mattei3, John Cheville4 and R. Jeffrey Karnes1*
Abstract
Localized prostate cancer (PCa) is a clinically heterogeneous disease, which presents with variability in patient
outcomes within the same risk stratification (low, intermediate or high) and even within the same Gleason scores.
Genomic tools have been developed with the purpose of stratifying patients affected by this disease to help
physicians personalize therapies and follow-up schemes. This review focuses on these tissue-based tools. At present,
four genomic tools are commercially available: Decipher™, Oncotype DX®, Prolaris® and ProMark®. Decipher™ is a
tool based on 22 genes and evaluates the risk of adverse outcomes (metastasis) after radical prostatectomy (RP).
Oncotype DX® is based on 17 genes and focuses on the ability to predict outcomes (adverse pathology) in very
low-low and low-intermediate PCa patients, while Prolaris® is built on a panel of 46 genes and is validated to
evaluate outcomes for patients at low risk as well as patients who are affected by high risk PCa and post-RP. Finally,
ProMark® is based on a multiplexed proteomics assay and predicts PCa aggressiveness in patients found with
similar features to Oncotype DX®. These biomarkers can be helpful for post-biopsy decision-making in low risk
patients and post-radical prostatectomy in selected risk groups. Further studies are needed to investigate the
clinical benefit of these new technologies, the financial ramifications and how they should be utilized in clinics.
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Background
Prostate cancer (PCa) represents the most commonly di-
agnosed internal malignancy among men in the Western
world. In 2015, the number of men diagnosed with PCa
was estimated to be over 220,000 in the United States
alone [1]. The introduction of prostate-specific antigen
(PSA) in the late 80s and the associated ‘stage migration’
have led to an increase of PCa diagnoses and specifically
lower risk disease [2]. Although a number of these newly
diagnosed patients are potentially eligible for active
surveillance (AS), a large percentage still undergo ac-
tive treatment given some uncertainty as to whether
they harbor a ‘higher risk’ disease. Additionally, the
number of patients diagnosed with high risk disease
with an elevated risk of metastasis and death is still
considerable, and an increasing trend has been de-
scribed [3, 4]. In this setting, it is pivotal to increase
our ability over-and-above routine clinicopathologic
variables (T stage, PSA, Gleason scores and other
cancer characteristics from biopsies and/or pathology
specimens) to identify patients that could benefit
from an active treatment after prostate biopsy, as well
as patients that are at added risk for recurrence(s)
after radical prostatectomy (RP). This is fundamental
considering the potential morbidity associated with
any active treatment, such as radiation and/or RP for
PCa. None of the above represents novel concepts;
however, there now exists biomarkers that may allow
for better risk stratification to help decide on treatment
versus no treatment. Patients can often be categorized into
subgroups using the routine clinicopathologic parameters.
However, better understanding of PCa biology using
tissue-based biomarkers might help clinicians provide
more ‘personalized’ treatments.
In this context, not only is the clinical behavior of PCa
heterogeneous but so are the genomic alteration pat-
terns within the biologic pathways, and several different
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mutations are needed during tumorigenesis to develop an
aggressive PCa. For this reason, studying and cataloging
these albeit quite complex alterations [5–7] has contrib-
uted to the need for development of complex biomarkers
or genomic panels that are combined to improve prognos-
tication of localized PCa, and more so to tailor both pri-
mary or secondary treatment and follow-up. Clinicians,
most frequently urologists, are often challenged how to
best advise newly diagnosed male patients with low-to-
intermediate (3 + 4) risk prostate cancer, to undergo active
surveillance versus active treatment, and patients are often
left wanting more information to make that decision. Even
after a PCa has been treated by a RP, patients with adverse
pathology (non-organ-confined disease) or those that de-
velop biochemical recurrence (BCR) have a disparate risk
of developing metastasis, and secondary treatment, often
radiation, is advocated. As alluded earlier, there are inher-
ent limitations in the ability to prognosticate a potentially
lethal cancer using pathology reports and PSA values.
Genomic sequencing of advanced PCa highlights the com-
plexity of this disease and its different states [8, 9]. In this
context, biomarker panels or genomic tools have been de-
veloped for more localized disease that perhaps help to
‘simplify’ a response to a complex question, i.e. is there a
lethal component of this hormone-sensitive PCa in the
treatment-naïve state or post-RP? The information pro-
vided by these tools are presented as a risk percentage; for
example, the percentage risk of upgrading from biopsy to
a higher Gleason score, such as 4 + 3 at RP, or percentage
chance of BCR or metastasis after RP. These tools do not
provide a binary answer to treat or not to treat for the
clinician or patient. They use archived formalin-fixed,
paraffin-embedded (FFPE) tissue of either the highest vol-
ume tumor foci or Gleason score from either a biopsy or
RP specimen. Each assay is unique. To date, there are no
head-to-head studies evaluating one of these panels over
the other when a comparison is relevant. Prior to these
biomarker or genomic panels, there were no routine
tissue-based biomarkers that were used in practice. As
mentioned, the goal is early detection of a potentially
‘lethal’ PCa to treat and separation of this from a poten-
tially indolent course. The development of metastasis is
usually lethal despite survival gains by different systemic
therapies [10–14]. Considering the vast research and data
in this field, several previous reviews assessed the import-
ance of tissue-based biomarkers [15–18]. In this context,
we present an up-to-date overview of available tissue
markers correlated with clinical utility in the field of PCa.
Commercially available tissue-based prognostic
biomarker panels
Decipher™
Decipher™ is a genomic test, co-developed by GenomeDx
Biosciences (Vancouver, BC, Canada) and Mayo Clinic, to
assess the probability of developing metastases after RP
(Table 1). This tool was developed by analyzing 1.4 million
genomic markers, including coding and non-coding RNA.
The signature is based on 22 expressed RNA biomarkers
involved in various biologic pathways (cell differentiation,
proliferation, structure, adhesion and motility, immune
modulation, cell-cycle progression, androgen signaling)
[19]. The outcome of the test is represented by a derived
continuous risk score—a genomic classifier (GC) ranging
from 0 to 1. Each score has an associated probability of
metastasis at 5 years postoperatively, with 1 being the
highest risk. Specifically, Decipher™ has been studied and
approved in the United States for PCa patients treated
with RP and adverse pathology (pT3 and/or positive mar-
gins or BCR) to evaluate the risk of developing BCR or
clinical progression (metastasis) during follow-up. How-
ever, although these recommendations have been reported
in the National Comprehensive Cancer Network (NCCN)
guidelines [20], clinical use and long-term data are needed
to judge the real added value [16].
Natural history after BCR in RP PCa patients
Alshalalfa et al. [21] analyzed the differences in patients
that developed BCR, clinical metastases or were free
from any adverse outcomes during follow-up, and found
that Decipher™ can represent a useful tool to better
prognosticate patients who develop metastasis after
BCR. In this study, patients without evidence of disease
and those with BCR-only were found with similar tran-
scriptional profiles, in contrast to patients that devel-
oped metastases and showed a distinct transcriptional
profile that can be detected in the primary tumor/RP
specimen. These findings were validated in 219 high risk
PCa patients treated at Mayo Clinic with RP. On multi-
variable analyses, higher GC scores were most prognos-
tic for the development of metastases [22]. Similar
results were observed by Ross et al. [23] with 85 high
risk patients who developed BCR after RP. Moreover,
with this natural history study, i.e. without secondary
treatments potentially confounding the results, the GC
score was able to differentiate between patients that
eventually progress after BCR and those that do not,
indicating perhaps the patients to earlier intervene on
versus those that might continue to be followed.
Immediate versus delayed adjuvant radiotherapy
after RP Den et al. [24] studied patients treated by RP
and adjuvant radiotherapy (aRT) for pT3 or positive
surgical margin PCa, and found the area under the
curve (AUC) predicted BCR and clinical metastases of
78 % and 80 %, respectively. Patients with a lower
GC score on their RP specimen were those who may
benefit from delayed RT at further BCR, in comparison to
patients with higher GC who may benefit from aRT. In a
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follow-up study [25], 188 patients from both Thomas
Jefferson University and Mayo Clinic treated with RP and
adjuvant or salvage RT were evaluated with a median
follow-up of 10 years. The GC score was able to best prog-
nosticate the occurrence of metastases, and provided fur-
ther support that patients with low GC scores can
probably be treated with observation and salvage RT as
needed, while patients with high GC scores could benefit
the most from aRT. This is a step towards balancing the
risks and benefits of delivering aRT, since all these male
patients would have been advised to consider aRT based
on their RP pathology, and evidence that the GC score is
not only prognostic but potentially predictive in regards to
the timing of postoperative RT. Furthermore, a study by
Lobo et al. [26] showed a benefit in quality-adjusted life-
years (QALYs) by using the Decipher™ test in the postop-
erative setting.
Combination of validated clinical and genomic risk
stratification for prediction of survival after RP An
improvement in the prognostication of clinical out-
comes after RP has been described by Klein [27] and
Cooperberg [28] by including validated clinical pa-
rameters and Decipher™ scores in the same model.
The AUC in prognostication of metastases was 77 %,
75 % and 72 % for Decipher™, and the commonly
used clinical scores from the Stephenson model and
Cancer of the Prostate Risk Assessment Score (CAPRA-S),
respectively. However, when Decipher™ was integrated into
the Stephenson nomogram, the AUC rose to 79 %. Similar
results were presented for cancer-specific mortality (CSM)
after RP; in fact, the AUCs were 75 % and 78 % for
CAPRA-S and Decipher™, respectively. Patients with both
high GC and CAPRA-S risk scores were at major risk for
CSM. Moreover, Decipher™ was able to reclassify many
patients stratified to high risk based on CAPRA-S to an
actual lower risk based on a low GC, thus potentially spar-
ing patients postoperative therapy, and at least providing
less worry to the patients.
Oncotype DX®
Oncotype DX® is a test that has been developed by
Genomic Health (Redwood City, CA, USA) for prostate
cancer, and is well known for its prognostic and predict-
ive capability in breast oncology. This tool is a quantita-
tive RT-PCR assay performed on FFPE tissue from
needle biopsies, incorporating 12 cancer-related genes
representing four biological pathways (stromal response,
androgen signaling, proliferation, cellular organization)
and five reference genes, which are algorithmically com-
bined to calculate the Genomic Prostate Score (GPS)
[29]. The derived GPS ranges from 0 to 100, with the
higher number correlating with a higher probability of
harboring adverse pathology at RP in men diagnosed
with low or low-intermediate risk prostate cancer at
prostate biopsy (Table 2). Ostensibly, this test is utilized
Table 1 Characteristics of studies evaluating Decipher™
First author and year Number of cases Study population End point Main results
Erho et al. [19] 2013 545 patients Radical Prostatectomy Metastases Area Under Curve of 75 % in
prediction of metastases
Karnes et al. [22] 2013 219 patients Radical Prostatectomy Metastases Area Under Curve of 79 % in
prediction of metastases
Den et al. [24] 2014 139 patients Radical Prostatectomy and
adjuvant radiation therapy
Biochemical recurrence and
metastases
Area Under Curve of 78 %
and 80 % in prediction of
biochemical recurrence and
metastases, respectively
Ross et al. [23] 2014 85 patients Radical Prostatectomy Metastases after biochemical
recurrence
Area Under Curve of 82 % in
prediction of metastases in
patients that have developed
Biochemical recurrence
Cooperberg et al. [28] 2015 185 patients Radical Prostatectomy Disease free survival Predict high risk for PCa death
Den et al. [25] 2015 188 patients Radical Prostatectomy and
adjuvant radiotherapy in
pT3 or positive margin
patients
Metastases Predict development of clinical
metastases
Klein et al. [27] 2014 162 patients Radical Prostatectomy for
high risk prostate cancer
in node positive patients
Metastases within 5 year
after surgery
Predict development of
metastases within 5 years
after surgery
Alshalalfa et al. [21] 2015 463 patients Radical Prostatectomy Differences between patients
that developed Biochemical
recurrence or metastasis
during follow up
Patients that develop
metastases after BCR can
be identified
Moschini et al. BMC Medicine  (2016) 14:67 Page 3 of 7
to counsel men regarding the best course of therapy
(active surveillance vs. treatment) in newly diagnosed
low or low-intermediate PCa. Specifically, NCCN guide-
lines recommend its utilization in post-biopsy decision-
making for NCCN very low and low risk PCa at diagno-
sis with 10–20 years’ life expectancy [20].
Prediction of survival outcomes in low or intermediate
risk PCa Klein et al. [30] designed an initial study in-
cluding 395 men who had low to intermediate risk
prostate cancer who underwent RP. The biopsy-based
17-gene GPS improved on the prediction of the pres-
ence or absence of adverse pathology, defined as pri-
mary Gleason score pattern of 4 or any pattern of 5,
or non-organ-confined disease. Cullen et al. [31] de-
scribed 431 patients with NCCN very low, low and
intermediate risk-stratified PCa at biopsy, and demon-
strated the ability of Oncotype DX® on a biopsy speci-
men (largest tumor foci) to independently better
predict adverse pathology at RP and consequently
BCR than the risk group variables.
Prolaris®
Prolaris® is also a prognostic test developed by Myriad
Genetics (Salt Lake City, UT, USA). This test is based on
the expression of 31 cell-cycle progression (CCP) and 15
housekeeping genes (Table 3), and is an extension of
their breast cancer test. The result is represented by a
proliferative index, expressed as a CCP score [32]. The
result has shown improved prognostic ability over
clinicopathologic variables in various settings and tis-
sues (biopsy and RP), and for various outcomes. This
tool is used on biopsies from low and very low risk
men to help better determine if immediate or deferred
(conservatively managed) treatment is the better course.
Again, like others, it is a prognostic assay and does not
provide an answer to the treatment conundrums, but a
probability of an event in the future, such as BCR and
prostate cancer-specific mortality. In context, NCCN rec-
ommends its use in the post-biopsy period for NCCN very
low and low risk PCa at diagnosis for patients with at least
10 years’ life expectancy [20].
Prediction of survival outcomes in low or very low
risk patients Cuzick et al. [33] investigated 349 pros-
tate biopsy samples evaluating the impact of CCP
score—Prolaris®—on disease-free survival. At multivari-
able analysis, the CCP score showed a hazard ratio of
1.65, which was the strongest factor. Bishoff et al. [34]
analyzed 582 patients from the Martini Clinic (n = 283),
Durham Veterans Affairs Medical Center (n = 176) and
Intermountain Healthcare (n = 123), and showed an as-
sociation of the biopsy CCP score with adverse out-
comes after surgery. In a larger study, Cuzick et al. [32]
evaluated the CCP score and its ability of prognosticat-
ing BCR in a US cohort of RP patients and mortality in
a UK cohort of patients treated with transurethral resec-
tion of the prostate (TURP). Additionally, the CCP was
validated by Freedland et al. [35] in primary external
radiation-treated patients. Cooperberg et al. [36] ana-
lyzed 413 RP patients with a CCP score in prognosticat-
ing BCR, and the best AUC came from a combined CCP
score and CAPRA-S for the overall cohort and the low
risk subset.
Table 2 Characteristics of studies evaluating OncotypeDX®
First author and year Number of
cases
Study population End point Main results
Klein et al. [30] 2014 608 patients Radical prostatectomy and
Prostate biopsies
Metastases after radical prostatectomy
and adverse pathology in radical
prostatectomy specimen
Prediction of adverse pathology
at radical prostatectomy using
prostate biopsies tissue.
Cullen et al. [31]
2015
431 patients Prostate biopsies in very low,
low and intermediate Prostate
cancer patients
Adverse radical prostatectomy pathology
and biochemical recurrence
Increased BCR risk at univariable
analyses and after adjusting for
risk groups at multivariable using
prostate biopsy tissue
Table 3 Characteristics of studies evaluating Prolaris®
First author and year Number of cases Study population End point Main results
Cuzick et al. [32] 2011 703 patients Transurethral resection of prostate
or radical prostatectomy
Biochemical recurrence and
disease free survival
Predict biochemical recurrence
and disease free survival
Cuzick et al. [33] 2012 349 patients Prostate biopsies Disease free survival Predict disease free survival
Cooperberg et al. [36] 2013 413 patients Radical prostatectomy Biochemical recurrence Predict biochemical recurrence
Freedland et al. [35] 2013 141 patients Prostate biopsies in patients
treated with EBRT
Biochemical recurrence and
disease free survival
Predict disease free survival
Bishoff et al. [34] 2014 582 patients Prostate biopsies Biochemical recurrence and
metastases
Predict biochemical recurrence
and metastases
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ProMark®
ProMark® is the newest commercially available bio-
marker panel and is a protein-based test developed by
Metamark (Cambridge, MA, USA) as a quantitative
multiplexed proteomics assay. Originally, there were 12
protein markers that demonstrated the best prognostica-
tion from a biopsy specimen [37]. Subsequently, the sig-
nature was refined and includes eight protein markers
[38], with a score (0–1) reflecting the probability of
adverse pathology at RP. To our knowledge, there is a
lack of validation of this panel, most likely related to the
more recent development.
Prediction of aggressiveness of prostate biopsy samples
Blume-Jensen et al. [38] found a favorable biomarker risk
score (defined as ≤ 0.33) and a non-favorable risk score
(defined as > 0.80) in 10 % and 5 % patients, respectively.
The predictive value for non-favorable pathology was
76.9 % considering a biomarker risk score of > 0.80. At a
biomarker risk score of ≤ 0.33 evaluating the prediction of
favorable pathology disease, the predictive values were
95 %, 81.5 % and 87.2 % in NCCN very low and low risk,
and low risk D’Amico groups, respectively [38].
ConfirmMDx
ConfirmMDx is a methylation marker genetic test devel-
oped by MDxHealth (Irvine, CA, USA). The test records
a 90 % negative predictive value within 30 months of the
initial biopsy, and has been reported as the most signifi-
cant predictor of biopsy results [39]. The impact of this
test on re-biopsy was recently assessed in 138 patients;
among those with a negative ConfirmMDx assay, only
6 patients (4 %) underwent repeat biopsies [40].
ConfirmMDx may therefore be of value in the decision of
repeat biopsies after a negative initial prostate biopsy.
Other available tissue-based markers
Ki-67
Ki-67 is a nuclear protein associated with ribosomal
RNA synthesis and has been typically measured by semi-
quantitative immunohistochemistry (IHC) to assay cell
proliferation in cancer. Although not tied to a commer-
cial entity nor licensed, the IHC is typically performed
using a MIB-1 antibody and reported as a percent of
cells staining positively, which reflects their proliferation
and correlates with various cancer outcomes, including
PCa. Although several reports have assessed the impact
of Ki-67 evaluation at the time of biopsy or after RP, at
the present time no clinical use has been recommended
by NCCN, which recently excluded the use of this test
from the recommendation [20].
Prostate biopsies The prognostic value of K1-67 in
prostate needle biopsies are documented by several
authors [41–43]. Tollefson et al. [44] most recently re-
ported data of 451 consecutive patients with biopsy-
proven PCa treated with RP at Mayo Clinic. The results
confirmed that a combination of Gleason score, perineu-
ral invasion and Ki-67 expression is the most effective
predictor of cancer outcome at the time of prostate nee-
dle biopsy. It is not known how this single marker of cell
proliferation compares to the CCP. Ki-67 staining index
on biopsies has been tested on 573 patients treated with
PCa radiotherapy with a median follow-up of 96 months
[45]. The Ki67 staining index was the most significant
determinant of distant metastases and cancer-specific
mortality during follow-up.
Outcomes after radical prostatectomy for localized
PCa Ki-67 staining index has also been reported to be a
powerful predictor of survival after RP [42, 46, 47]. Fur-
thermore, Mathieu et al. [48] analyzed data of 3,123 pa-
tients who underwent RP and confirmed that Ki-67 is a
strong prognostic variable for BCR, and might be in-
formative in clinical decision-making regarding adjuvant
therapy and optimizing follow-up schedules.
PTEN
Considering mutations that have a well-established role in
PCa, dysregulation of PTEN seems to be involved more
frequently than others in advanced, localized or metastatic
PCa, and has shown a prognostic impact [49–52]. PTEN
is located on chromosome 10 and its mutation is consid-
ered a part of the PI3K/AKT signaling pathway and func-
tions as a tumor suppressor gene. PTEN appears to be the
most frequently mutated tumor suppressor gene and dele-
tion of PTEN has been recorded in 10–70 % of RP speci-
mens [53–57], with the variability likely related to the risk
group, with the higher the risk the higher likelihood of a
PTEN deletion. A recent publication by Murphy et al. [58]
demonstrated that PTEN loss is infrequent in clinically in-
significant PCa (Gleason score 6 and low volume) and is
associated with higher-grade tumors. This finding is also
supported by others whether on biopsy [59, 60] or RP
specimens [49, 61] and in castration-resistant tumors [62].
Again, it is unknown how a single gene may perform in
relation to an aforementioned panel and what the prog-
nostic differences would be. The costs of a single gene
assay should be cheaper than a panel, but given the het-
erogeneity of PCa in terms of foci and different biologic
pathways there is an obvious potential to not completely
capture what is needed with a single marker. As per Ki-67
marker, its use has been excluded from the clinical recom-
mendation by NCCN [20].
Conclusions
Available genomic assays have improved the prognostic
ability over clinicopathologic parameters of localized
Moschini et al. BMC Medicine  (2016) 14:67 Page 5 of 7
PCa. Ideally, these assays should be prospectively ap-
plied, or even retrospectively applied to prospective
studies, to further validate their clinical utility in prog-
nostication and even prediction in terms of what treat-
ment should be applied either at a new diagnosis or
post-RP. In addition to their clinical value, more work is
needed in regards to their financial impact on the cost
of localized PCa care.
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